Adaptyv Bio

Headlines · 3

1. 2d
   Anthropic builds its own biology lab as Claude flags a novel enzyme system

   Reuters reported, and Anthropic life-sciences lead Eric Kauderer-Abrams confirmed, that the company has set up its own biology lab in the San Francisco Bay Area while continuing to work with outside labs. In an early result, about 950 Claude agents analyzed more than 200,000 reverse transcriptase sequences and flagged a new enzyme system, ART (array-associated reverse transcriptases), whose repeat arrays resemble CRISPR; experiments confirmed short RNA expression but not the system's function. In an earlier protein-design study, Claude did not replace specialist models such as RFdiffusion but organized them and filtered candidates, and 354 of 1,320 designs sent to an external lab bound their targets (about 26.8% hit rate), with successes on 14 of 15 targets.

   MIT科技评论中文 · 🔥 0
2. 4d
   AI pharma's pivotal test: Rentosertib Phase III readout due 2029

   The article reports that Anew Labs, an AI drug-discovery company spun out of ByteDance, raised a $290 million first round at a $1.5 billion valuation, and that Anthropic has reportedly built a wet lab in the San Francisco Bay Area where Claude drives robots to run real biological experiments. It divides the AI pharma chain into three groups — upstream AI technology firms such as Insilico Medicine, midstream CRO/CDMO wet-lab service providers such as GenScript and Twist Bioscience, and downstream pharma companies including Fosun Pharma and Hengrui Pharmaceuticals — and cites brokerage estimates that AI can cut drug-discovery timelines by 70%-90% and total R&D cost by roughly 50%. The decisive test is Insilico's lead asset Rentosertib, whose Phase IIa showed a 98.4 mL mean lung-capacity gain at 60 mg versus a 20.3 mL decline in controls; its China Phase III began in July 2026 with 320 planned participants and top-line data expected in 2029.

   36氪 人工智能 · 🔥 0
3. Oct 10
   AI drug design is flooding Chinese labs with wet-lab work

   Anthropic's Claude designed 1,320 binding proteins against a dozen targets, which Adaptyv Bio and Twist synthesized and tested; 354 were confirmed to bind, a hit rate near 30% versus the traditional 10%–15%. The article argues that as AI pushes the marginal cost of molecular design toward zero, the first orders flow to lab-service providers: GenScript's AIDD revenue doubled year over year in H1 with gross margins about 20 points above its traditional protein-expression business, while XtalPi posted 803 million yuan in 2025 revenue, tripled and its first full-year profit. Meanwhile Washington is trying to pull early-stage R&D and clinical capacity back onshore via HHS's TrialBlazer plan and the BIOSECURE Act.

   MIT科技评论中文 · 🔥 0

Experience and discussion from the community

Share my Adaptyv Bio experienceAsk about Adaptyv Bio